First pre-competitive project initiated

First pre-competitive project initiated

A key goal of the Milner Therapeutics Consortium is to enable collaborations between Cambridge academics and our Consortium companies using forward-thinking pre-competitive models. We can now announce that the first such project has been established with Ludovic...
New University Enterprise Zone announced

New University Enterprise Zone announced

The Milner Therapeutics Institute will form part of a University Enterprise Zone, created through a new government initiative announced today by Universities Minister Chris Skidmore. Research England, part of UK Research and Innovation, today announced 20 new...
Welcome to Pathania group

Welcome to Pathania group

We are delighted to welcome the group of Manav Pathania (Dept Oncology), who moved into the Milner Institute this month. The Pathania group have a central focus on developing new mouse models for children’s brain tumours, to better understand the diverse genetic basis...
Renewal of Milner Therapeutics Consortium

Renewal of Milner Therapeutics Consortium

We are delighted to announce that the Milner Therapeutics Consortium has been renewed until 2024. The Consortium includes 7 pharma companies (Astex, AstraZeneca, Ferring, GlaxoSmithKline, J & J Innovation, Pfizer, Shionogi) who are committed to collaboration and...
Medical Advancement Institute of the Year 2017

Medical Advancement Institute of the Year 2017

We are privileged to receive the Medical Advancement Institute of the Year award from AI Global Media. The award is in recognition of our global alliance, which we have increased from 6 organisations in 2015 to 65 organisations in 2017. Our alliance enables...

MILNER THERAPEUTICS SYMPOSIUM

X